CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


FNC+Standard of CareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug915 FNC dummy tablet+Standard of Care Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Randomized,Double Blinded, Double Dummy, Parallel Controlled Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

To evaluate the efficacy and safety of azvudine in treatment of COVID-19

NCT04425772 COVID-19 Drug: FNC+Standard of Care Drug: FNC dummy tablet+Standard of Care
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: (reduction) in viral load from baseline

Measure: Change (reduction) in viral load from baseline

Time: On day 7 and 14

Secondary Outcomes

Description: proportion of subjects change from mild or moderate type to severe type

Measure: proportion of subjects change from mild or moderate type to severe type

Time: up to 21 days

Description: proportion of subjects change from severe type to critical type

Measure: proportion of subjects change from severe type to critical type

Time: up to 21 days

Description: novel coronavirus nucleic acid conversion rate

Measure: novel coronavirus nucleic acid conversion rate

Time: up to 21 days

Description: Novel coronavirus nucleic acid negative conversion time

Measure: Novel coronavirus nucleic acid negative conversion time

Time: up to 21 days

Description: TIme(Days);Proportion(percent)

Measure: The time and proportion of improvement in pulmonary imaging

Time: up to 21 days

Description: TIme(Days);Proportion(percent)

Measure: Time and proportion of temperature return to normal

Time: up to 21 days

Description: TIme(Days);Proportion(percent)

Measure: time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)

Time: up to 21 days

Description: TIme(Days);Proportion(percent)

Measure: time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms

Time: up to 21 days

Description: Changes of blood oxygen detection index

Measure: Changes of blood oxygen detection index

Time: up to 21 days

Description: Frequency of requirement for supplemental oxygen or non-invasive ventilation

Measure: Frequency of requirement for supplemental oxygen or non-invasive ventilation

Time: up to 21 days

Description: Frequency of adverse events

Measure: Frequency of adverse events

Time: up to 21 days


Related HPO nodes (Using clinical trials)